A Study to Evaluate the Long Term Safety and Effectiveness of Novantrone Therapy Followed by Copaxone Treatment for Multiple Sclerosis
NCT00203086 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30
Last updated 2010-04-29
Summary
It is thought that treating Multiple Sclerosis with Novantrone for a short period of time prior to treatment with Copaxone may enhance the onset effect of Copaxone.
Conditions
- Relapsing Remitting Multiple Sclerosis
Sponsors & Collaborators
-
Teva Branded Pharmaceutical Products R&D, Inc.
lead INDUSTRY
Principal Investigators
-
Lillian Pardo, MD · Teva Neuroscience, Inc.
Eligibility
- Min Age
- 20 Years
- Max Age
- 57 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2005-10-31
- Primary Completion
- 2009-10-31
- Completion
- 2009-12-31
More Related Trials
-
Study Evaluating Mitoxantrone in Multiple Sclerosis
NCT00146159 ·Status: TERMINATED ·Phase: PHASE3
-
A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose
NCT00202982 ·Status: COMPLETED ·Phase: PHASE2
-
Prospective, Open-label Tolerability and Safety Monitoring Study of Novantrone in a Selected Cohort of Multiple Sclerosis Patients
NCT00262314 ·Status: COMPLETED
-
Evaluation of a New Therapeutic Strategy in Early and Active Relapsing-Remitting Multiple Sclerosis
NCT00219908 ·Status: TERMINATED ·Phase: PHASE2
-
Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
NCT01464905 ·Status: UNKNOWN ·Phase: PHASE3
-
Safety Study of Natalizumab to Treat Multiple Sclerosis (MS)
NCT00559702 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Comparing Shared Solutions® Plus MS Center Support Versus Shared Solutions® Alone
NCT00240006 ·Status: COMPLETED ·Phase: PHASE4
-
Study of the Safety and Efficacy of MLN1202 in Patients in Multiple Sclerosis
NCT01199640 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Tolerability of Glatiramer Acetate
NCT01874145 ·Status: COMPLETED ·Phase: PHASE3
-
Natalizumab Subcutaneous Immunogenicity and Safety Study
NCT02142192 ·Status: TERMINATED ·Phase: PHASE2
-
Combination Therapy With Avonex and BiMonthly High Dose Intravenous Methotrexate in Multiple Sclerosis
NCT00037102 ·Status: COMPLETED ·Phase: PHASE4
-
A Safety Study of Combination Treatment With Avonex and Placebo-Controlled Dosing of Topamax in Relapsing-Remitting Multiple Sclerosis
NCT00217295 ·Status: UNKNOWN ·Phase: PHASE2
-
A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic's Disease)
NCT00304291 ·Status: COMPLETED ·Phase: PHASE4
-
Open-Label Natalizumab Safety Extension Study
NCT00276172 ·Status: COMPLETED ·Phase: PHASE3
-
Safety of New Formulation of Glatiramer Acetate
NCT00947752 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Natalizumab in Combination With Avonex in the Treatment of Multiple Sclerosis
NCT00030966 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis
NCT05265728 ·Status: TERMINATED ·Phase: PHASE3
-
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
NCT07282574 ·Status: RECRUITING ·Phase: PHASE2
-
National Multicenter, Controlled, Single-blind Study With Two Parallel Groups Evaluating the Safety and Efficacy of Sequential Treatment With Mitoxantrone and Interferon Versus Interferon Alone in Patients With Strong Risk of Progression in the Initial Phase of Multiple Sclerosis
NCT02937285 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients
NCT01167426 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
NCT06735248 ·Status: RECRUITING ·Phase: PHASE2
-
Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis
NCT00819195 ·Status: COMPLETED
-
Safety and Effectiveness of Two Doses of ABT-874 as Compared to Placebo in Subjects With Multiple Sclerosis (MS)
NCT00086671 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by Magnetic Resonance Imaging (MRI)(0812-003)(COMPLETED)
NCT00239655 ·Status: TERMINATED ·Phase: PHASE2
-
Efficacy and Safety of GTR in Comparison to Copaxone®
NCT01489254 ·Status: COMPLETED ·Phase: PHASE3